Silo Pharma signs LOI with Allucent for SPC-15 nasal spray Phase 1 development
Share
Silo Pharma (NASDAQ:SILO) announced a non-binding Letter of Intent (LOI) with Allucent (US) LLC to support the Phase 1 clinical development of SPC-15, a nasal spray formulation under investigation.
